| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| AGN | Allergan plc. | $184.29 | $62.56B | N/A |
Should Gilead Sciences Be Worried About Allergan?
https://www.fool.com/investing/2017/04/23/should-gilead-sciences-be-worried-about-allergan.aspx?source=iedfolrf0000001
Apr 23, 2017 - Gilead Sciences might want to pay attention to Allergan's aggressive expansion of its NASH program.
2
Allergan (AGN) Collaborates with Novartis to Treat NASH
http://www.zacks.com/stock/news/256887/allergan-agn-collaborates-with-novartis-to-treat-nash?cid=CS-ZC-FT-256887
Apr 19, 2017 - Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
0
Did Pharma & Biotech M&As Pick Pace in Q1?
http://www.zacks.com/stock/news/256645/did-pharma-biotech-mas-pick-pace-in-q1?cid=CS-ZC-FT-256645
Apr 18, 2017 - Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.
0
Aerie Reports Positive Data on Ophthalmic Drug Rhopressa
http://www.zacks.com/stock/news/256284/aerie-reports-positive-data-on-ophthalmic-drug-rhopressa?cid=CS-ZC-FT-256284
Apr 13, 2017 - Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.
0
Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?
http://www.zacks.com/stock/news/254783/pharma-stock-roundup-fda-nod-for-sny-roche-drugs-generic-advair-relief-for-gsk?cid=CS-ZC-FT-254783
Mar 31, 2017 - Two drugs with blockbuster potential - Sanofi (SNY)/Regeneron's Dupixent and Roche's Ocrevus - gained FDA approval this week.
0
Why Equal Weighted Mutual Funds Scoring Over Index Funds
http://www.zacks.com/stock/news/254739/why-equal-weighted-mutual-funds-scoring-over-index-funds?cid=CS-ZC-FT-254739
Mar 30, 2017 - Investors interested in maintaining a diversified portfolio might consider investing in equal-weight funds.
0
Allergan Acne Candidate Meets Endpoints in Phase III Studies
http://www.zacks.com/stock/news/254397/allergan-acne-candidate-meets-endpoints-in-phase-iii-studies?cid=CS-ZC-FT-254397
Mar 28, 2017 - Allergan plc (AGN) in collaboration with Paratek Pharmaceuticals, Inc. (PRTK) has announced positive results from two phase III studies on sarecycline
0
Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
http://www.zacks.com/stock/news/254077/amgens-amgn-humira-biosimilar-receives-approval-in-eu?cid=CS-ZC-FT-254077
Mar 24, 2017 - Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).
0
Teva Pharma Denies Rumors of Global Workforce Reduction
http://www.zacks.com/stock/news/254066/teva-pharma-denies-rumors-of-global-workforce-reduction?cid=CS-ZC-FT-254066
Mar 24, 2017 - According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.
0
AstraZeneca Stock Rising in '17: What's Working in its Favor?
http://www.zacks.com/stock/news/253879/astrazeneca-stock-rising-in-17-whats-working-in-its-favor?cid=CS-ZC-FT-253879
Mar 23, 2017 - Shares of London-based pharma giant, AstraZeneca plc (AZN) have risen 13.4% this year so far, while the Zacks classified Large-Cap Pharma industry increased 6.4%.
0